Navigation Links
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

ents, should be sufficient to fund operating expenses, scheduled debt obligations and capital equipment requirements into the first half of 2009.

Third Quarter Highlights and Recent Developments

-- Expanded Development Program for R3487/MEM 3454 with Roche. In September 2008, Memory Pharmaceuticals and Roche amended their nicotinic alpha-7 receptor agonist agreement, resulting in accelerated milestone payments to the Company. The companies agreed to expand the ongoing Phase 2 study of R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS) to provide for a more robust data set and increase the potential for the study to facilitate advancing the compound into a pivotal trial. The Company received $3.5 million in connection with the amendment and will receive $5.0 million upon the enrollment of the 212th patient in the trial, which is expected to occur in November 2008. An additional $8.5 million will become due 30 days following the availability of top-line data from the Phase 2 CIAS trial. In addition, Roche has agreed to fund all internal and external costs associated with expanding the trial.

-- Received Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908. In October, Memory Pharmaceuticals announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists including R3487/MEM 3454 and R4996/MEM 63908. The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

-- Completed Phase 1 Program for R4996/MEM 63908. In September, the Company completed its Phase 1 multiple ascending dose study of R4996/MEM 63908 in healthy volunteers. The trial is the fourth and final study in the Company's Phase 1 program for the compound. The Company expects to announce top-line results from the entire Phase 1 program in the fourth quarter of 2008.

-- Presentations at Scientific Meeting
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Miniaturizing memory: Taking data storage to the molecular level
2. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
6. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
7. Jellyfish Protein Shows Potential to Help With Memory
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... critical, yet often overlooked factor in the medical ... effects of aggregation on both radiofrequency heating and ... oxide nanoparticles (IONPs), including detailed analysis of the ... is shown to produce significant reductions in both ... new method to quantify and correlate these effects ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma Inc. ... recommended approach for protecting personal data in Clinical ... patients and others. The document describes an approach ... from CSRs and other related clinical trial documents, ... The goal of the TransCelerate CSR Redaction approach ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
Breaking Biology Technology:Accounting for biological aggregation in heating and imaging of magnetic nanoparticles 2UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... The Drug Information Association (DIA) will host two co-located ... ... Horsham, PA (PRWEB) ... (DIA)] will host two co-located conferences from October 23-24 ...
... your lap lately, you probably noticed a burning sensation. ... more heat, which has to go somewhere in ... the University of Virginia,s School of Engineering and Applied ... solve the problem using nanoelectronics, considered the essential science ...
... 29 If one Delaware man,s vision,comes true, ... tumors as,they are with breast cancer, and to ... in the Game(R), an awareness campaign in his ... Kelly Heinz-Grundner Brain Tumor Foundation,and early this month ...
Cached Biology Technology:DIA Co-located Conference to Examine Outsourcing and Project Management Best Practices 2Engineers aim to solve 'burning' computer problem 2Delaware Man Spearheads Brain Tumor Awareness 2
(Date:9/2/2014)... the same DNA sequence their genetic information. How ... in the different parts of the body are so ... master plan, an additional regulatory layer exists that determines ... This mechanism involves modifications of genome-bound histone proteins or ... It acts on top of the genetic information and ...
(Date:9/2/2014)... in the September issue of The FASEB ... strategy to diagnose the leading cause of blindness ... has occurred. This advance involves quantifying the early ... of retinal vessels. Using new probes developed by ... molecular development of diabetic retinopathy. , "My goal ...
(Date:9/2/2014)... D.C., September 2, 2014 A study published ... Journal of the American Academy of Child and ... diagnosed with a psychiatric diagnosis had an increased ... to antipsychotics. , Using data from the nationwide ... Dr. Ren Ernst Nielsen, Psychiatry, Aalborg University Hospital, ...
Breaking Biology News(10 mins):Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Risk of diabetes in children and adolescents exposed to antipsychotics 2
... world,s subspecies of tigers are now extinct. A new study ... a result of human activities, particularly the conversion of natural ... The study, conducted by Virginia Tech and World Wildlife ... investigate the use of different land cover types not ...
... People with schizophrenia who completed 80 hours of intensive, ... complex tasks that required them to distinguish their internal ... Neuron (2/22/12), a small clinical study conducted ... the University of California, San Francisco (UCSF), tested the ...
... Biology Department Chairman Thomas Chiles has been named the ... of Biology, the university announced today. Chiles, whose ... by the National Cancer Institute, the National Institutes of ... receive the endowed professorship, which will support his ongoing ...
Cached Biology News:Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 2Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 3Schizophrenia patients' ability to monitor reality may be helped by computerized training 2Schizophrenia patients' ability to monitor reality may be helped by computerized training 3Boston College names Thomas Chiles the Deluca Professor of Biology 2
...
solute carrier family 25, member 13 (citrin)...
... Ladder is suitable for sizing ... 16 kb by agarose gel ... be visualized by ethidium bromide ... detected on Southern blots by ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: